Intuitive Surgical (ISRG) stock is down 34% in 2026. We analyze whether the da Vinci 5 recurring revenue moat and 30% consensus upside make the de-rating a buying opportunity.
Intuitive Surgical (ISRG) da Vinci procedure growth fears drove a 40%+ selloff. At 29x forward earnings with a wide moat, here is why ISRG is a Buy.
Intuitive Surgical dominates robotic surgery with 80% market share. Q1 2026 revenue surged 23% as da Vinci 5 adoption accelerates. Buy rating with $530 target.
Intuitive Surgical stock analysis: ISRG dominates the B surgical robotics market with 67% share, da Vinci 5 Force Feedback technology, and 83% recurring revenue from 9,500+ installed systems.
